Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors
US10568888B2 · kind B2 · utility
1Cited by
4References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 10, 2019 |
| Grant date | Feb 25, 2020 |
| Priority date | — |
| Expiry date | Jul 10, 2039 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-α or by PDE4 including, but not limited to, allergic rhinitis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.